Pfizer raises FY2026 revenue outlook to USD 60.5-62.5 billion
Reuters2026/08/04 15:11- Pfizer raised the midpoint of its 2026 revenue guidance by USD 500 million to USD 60.5 billion-USD 62.5 billion.
- Updated outlook reflects stronger non-COVID performance, offset by lower COVID-19 revenue expectations of about USD 4 billion versus about USD 5 billion.
- Adjusted diluted EPS guidance reaffirmed at USD 2.8-USD 3 despite an expected USD 0.1 hit from a USD 650 million acquired IPR&D charge.
- Second-quarter revenue was USD 15 billion, up 1% operationally; adjusted diluted EPS was USD 0.77.
- Plan assumes most Comirnaty sales land late in the year; low COVID-19 incidence seen limiting Paxlovid utilization.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
JPMorgan resumes coverage of Lithium Americas (LAC.US) and upgrades to "Overweight", target price of $6.
Lithium Americas (LAC.US) shares rose 6% on Wednesday after JPMorgan resumed coverage and raised its rating to "Overweight" with a target price of $6.
Charlie Hospital Semarang says no material information behind share-price volatility
Venteny Fortuna International files corrected annual public expose materials
Abu Dhabi Mubadala Strategic Investment in Luckin Coffee Explained: Transfer of Preferred Shares by New and Old Funds, Transaction Size Around 1 billion USD
The beneficial ownership of Dachen remains unchanged.
Crypto prices
More
